Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
10 reports, 4 independent
Updated Mon 00:00
Mostly repetition
Reached 4 outlets in its first 24 hours
- Reports
- 10
- Developments
- 3
- Repetition
- 70%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BioVie held a clinical meeting in San Diego while listed on Nasdaq.1 source
Biovie submitted analyses to the FDA while listed on the Nasdaq exchange.1 source
BioVie announces CEO appointment, NASDAQ listing, and FDA review status for its drug candidate.1 source
Keep exploring
The entities involved
Related events
- Nexalin Technology, Inc. is listed on Nasdaq, pursuing FDA marketing authorization for DIFS technology, and announced a distribution agreement in Brazil.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.